Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2005-11-29
2005-11-29
Epps-Ford, Janet L. (Department: 1635)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C435S130000, C435S139000, C530S387100, C530S387700, C530S387900
Reexamination Certificate
active
06969518
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.
REFERENCES:
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5240856 (1993-08-01), Goffe et al.
patent: 5668267 (1997-09-01), Watson et al.
patent: 5855889 (1999-01-01), Watson et al.
patent: 5891857 (1999-04-01), Holt et al.
patent: 5922836 (1999-07-01), Watson et al.
patent: 5968754 (1999-10-01), Watson et al.
patent: 5986170 (1999-11-01), Subjeck
patent: 6004756 (1999-12-01), Watson et al.
patent: WO 89/06280 (1989-07-01), None
patent: WO 91/16116 (1991-10-01), None
patent: WO 92/07243 (1992-04-01), None
patent: WO 96/29430 (1996-09-01), None
patent: WO 98/21331 (1998-05-01), None
patent: WO 98/33915 (1998-08-01), None
patent: WO 98/54963 (1998-12-01), None
patent: WO 99/09155 (1999-02-01), None
patent: WO 00/08210 (2000-02-01), None
patent: WO 00/43420 (2000-07-01), None
patent: WO 00/60076 (2000-10-01), None
patent: WO 00/73801 (2000-12-01), None
patent: WO 01/37779 (2001-05-01), None
patent: WO 01/47959 (2001-07-01), None
patent: WO 01/51628 (2001-07-01), None
patent: WO 01/57270 (2001-08-01), None
patent: WO 02/059377 (2002-08-01), None
Chang et al. Critical Reviews in Oncology/Hematology. vol. 22, No. 3, Apr. 1996,pp. 213-228.
Kawakami et al. Cancer Science. Oct. 2004, vol. 95, No. 10, pp. 784-791.
Moutsopoulos et al. Molecular Medicine. 2000. vol. 6, No. 3, pp. 141-151.
GenBank Database, Accession No. AA219147, Feb. 7, 1997.
GenBank Database, Accession No. AI687645, May 27, 1999.
GenBank Database, Accession No. AL049911, Oct. 22, 1999.
GenBank Database, Accession No. AQ280806, Nov. 22, 1998.
Genseq Database (Thomson Derwent), Accession No. AAL25059, Dec. 7, 2001.
Genseq Database (Thomson Derwent), Accession No. AAV41453, Oct. 12, 1998.
Anderson and Seilhamer, “A comparison of selected MRNA and protein abundances in human liver,”Electrophoresis 18: 533-537, 1997.
Anderson, W.F., “Human gene therapy,”Nature 392(Supp): 25-30, Apr. 30, 1998.
Boon, T., “Toward a Genetic Analysis of Tumor Rejection Antigens,”Adv. Cancer Res. 58: 177-210, 1992.
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genove Research 10(4): 398-400, Apr. 2000.
Burgess, W.H. et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”Journal of Cell Biology 111: 2129-2138, Nov. 1990.
Curti, B.D., “Physical barriers to drug delivery in tumors,”Critical Reviews in Oncology/Hematology 14: 29-39, 1993.
Dermer, G.B., “Another Anniversary of the War on Cancer,”Biotechnology 12: 320, Mar. 1994.
Doerks, T. et al., “Protein annotation: detective work for function prediction,”Trends in Genetics 14(6): 248-250, Jun. 1998.
Ezzell, C., “Cancer ‘Vaccines’: An Idea Whose Time Has Come?”The Journal of NIH Research 7: 46-49, Jan. 1995.
Freshney, R.I.,Culture of Animal Cells. A Manual of Basic Technique, Alan R. Liss, Inc., New York, 1983, pp. 3, 4.
Gillies and Wesolowski, “Antigen binding and bilogical activities of engineered mutant chimeric antibodies with human tumor specificities,”Hum Antibod. Hybridomas 1(1): 47-54, 1990.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science 278: 1041-1042, Nov. 7, 1997.
Hartwell, L.H. et al., “Integrating Genetic Approaches into the Discovery of Anticancer Drugs,”Science 278: 1064-1068, Nov. 7, 1997.
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,”Scientific American 271(1): 58-65, Jul. 1994.
Lazar, E. et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Molecular and Cellular Biology 8(3): 1247-1252, 1988.
Russel and Barton, “Structural Features can be Unconserved in Proteins with Similar Folds. An Analysis of Side-chain to Side-chain Contacts Secondary Structure and Accessability,”J. Mol. Biol. 244: 332-350, 1994.
Skolnick and Fetrow, “Frome genes to protein structure and function: novel applications and computational approaches in the genomic era,”Trends in Biotechnology 18: 34-39, Jan. 2000.
Spitler, L.E., “Cancer Vaccines: The Interferon Analogy,”Cancer Biotherapy 10(1): 1-3, 1995.
Tao and Morrison, “Studies of aglycosylated chimeric mouse-human IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,”Journal of Immunology 143(8): 2595-2601, Oct. 15, 1989.
Chang and Shu, “Current status of adoptive immunotherapy of cancer,”Critical Reviews in Oncology/Hematology 22(3):213-228, Apr. 1996.
Cheever and Chen, “Therapy with cultured T cells: principles revisited,”Immunological Reviews, 157: 177-194, 1997.
Cheever et al., “Potential uses of interleukin 2 in cancer therapy,”Immunobiol. 172:365-382, 1986.
Chen et al., “T-cells for tumor therapy can be obtained from antigen-loaded sponge implants,”Cancer Research 54(4):1065-1070, Feb. 15, 1994.
Cole et al., “Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigent,”Cancer Research, 55:748-752, Feb. 15, 1995.
Durrant L., “Cancer vaccines,”Anti-Cancer Drugs, 8:727-733, 1997.
Eshhar Z., “Tumor-specific T-bodies: toward clinical application,”Cancer Immunol Immnother, 45:131-136, 1997.
Gen Bank Accession No. AC069200, May 24, 2000.
Gen Bank Accession No.AC036170, Apr. 9, 2000.
Gen Bank Accession No. AF269087, Mar. 28, 2001.
Gen Bank Accession No. AAK27325, Mar. 28, 2001.
Gen Bank Accession No. AA864891. Feb. 20. 1998.
Gen Bank Accession No. AA398925, Apr. 25, 1997.
Gen Bank Accession No. AL157387, Feb. 18, 2000.
Gen Bank Accession No. AL359312, Dec. 7, 2001.
Geneseq Accession No. V84525 (Dec. 10, 1998).
Hwu et al., “In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes,”Cancer Research, 55:3369-3373, Aug. 1, 1995.
Jäger et al., “Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library,”Cancer Research 61(5):2055-2061, Mar. 1, 2001.
Porter-Jordan and Lippman, “Overview of the biologic markers of breast cancer,”Breast Cancer 8:(1):73-100, Feb. 1994.
Prilliman et al., “HLA-B15 peptide ligands are preferentially anchored at their c termini,”The Journal of Immunology 162(12):7277-7284, Jun. 15, 1999.
Sulston et al., “Toward a complete human genome sequence,”Genome Research 8(11):1097-1108, 1998.
Stratagene 1991 product catalog, Prime-It™ Random Labeling Kit, catalog No. 300387, p. 66.
Wei et al., “Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2DNA,”Int. J. Cancer, 81:748-754, 1999.
Houghton Raymond L.
Persing David H.
Sleath Paul R.
Corixa Corporation
Epps-Ford Janet L.
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491712